Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
HIV Drug Not Tied to Premature Births

Pregnant HIV-infected women treated with a lopinavir/ritonavir (Kaletra)-based antiretroviral regimen are at no greater risk of delivering a preterm baby than similar pregnant women given an efavirenz (Sustiva)-based treatment, researchers said here.

Published
10 March 2013
From
MedPage Today
Bee Venom Destroys HIV And Spares Surrounding Cells

Nanoparticles containing bee venom toxin melittin can destroy human immunodeficiency virus (HIV) while at the same time leaving surrounding cells unharmed, scientists from Washington University School of Medicine reported in the March 2013 issue of Antiviral Therapy.

Published
10 March 2013
From
HIV / AIDS News From Medical News Today
New integrase inhibitor dolutegravir helps treatment-experienced people on failing therapy

The next-generation integrase inhibitor dolutegravir proved more beneficial than raltegravir (Isentress) for treatment-experienced people with resistance to two or more antiretroviral drug classes, researchers reported in a poster

Published
10 March 2013
By
Liz Highleyman
Second-line NRTI-sparing regimen proves equally effective for resource-limited settings

A second-line antiretroviral regimen of lopinavir/ritonavir (Kaletra/Aluvia) and raltegravir (Isentress) proved just as effective as a regimen containing lopinavir/ritonavir and two or three nucleoside or nucleotide analogues

Published
07 March 2013
By
Keith Alcorn
Funding Scientific Innovation: Global Investments in HIV Treatment Research and Development in 2010 and 2011

The latest report found US$2.6 billion was invested in HIV treatment R&D in 2011. Data from 41 public, private, and philanthropic donors reveal a 12% increase in funding from the baseline year of 2009, with the majority of funding targeted at research for new medications.

Published
07 March 2013
From
Treatment Action Group
Can people with resistant HIV omit NRTIs when switching from a failing regimen?

Omitting nucleoside reverse transcriptase inhibitors (NRTIs) when switching from a non-suppressive regimen to a new combination with at least two active agents can reduce pill burden and

Published
07 March 2013
By
Liz Highleyman
Transmission of Resistant HIV Steady

The rate of drug-resistant HIV transmission in the U.S. appears to be holding steady, according to the most recent CDC figures.

Published
07 March 2013
From
MedPage Today HIV/AIDS
Behind the miracle child a broken system lurks

While we celebrate this week’s story of an HIV-miracle cure, let’s not forget the story of injustice that made it possible. How is it possible for a pregnant woman in the world’s wealthiest country to not receive prenatal care? Why were the mother and child “lost to care” for over 6 months?

Published
07 March 2013
From
AIDS Foundation of Chicago
Long-term efavirenz linked to worse neurocognitive function in US CHARTER group

Long-term treatment with an efavirenz-based regimen correlated with worse neurocognitive function than did treatment with lopinavir/ritonavir, according to results of a retrospective case-control comparison within the US CHARTER cohort.

Published
07 March 2013
From
EATG / NATAP
New pro-drug tenofovir alafenamide appears equally effective but better tolerated

Tenofovir alafenamide fumarate or TAF (formerly GS-7340), a new pro-drug of the widely used NRTI tenofovir, reaches cells harbouring HIV more easily than the older tenofovir disoproxil

Published
07 March 2013
By
Liz Highleyman

Filter by country